NYSE · LLY
Eli Lilly and Company
$1,430.52+$56.82 (+4.14%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
Loading market information…
NASDAQ · OBLN · USD
Stock price, earnings
Quote as of Jun 16, 2021, 04:00 AM UTC. Cached market data; not a live quote.
Price history is currently unavailable.
Obalon Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.46% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Obalon Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Obalon Therapeutics, Inc. operates as a fully integrated medical device enterprise, concentrating its efforts on creating and commercializing innovative solutions for individuals battling obesity. The company's flagship offering is the Obalon Balloon System, specifically engineered to promote weight reduction in obese patients. This comprehensive system incorporates an ingestible capsule that houses an inflatable balloon connected to a microcatheter. It also includes the Obalon Navigation System console, a specialized hardware and software platform used to precisely monitor and display the balloon's location during its placement. Further components are the Obalon Touch Inflation Dispenser, a semi-automated, portable instrument for inflating the balloon once it's correctly positioned, and a single-use canister containing a gas mixture. By February 27, 2020, Obalon Therapeutics managed three company-owned treatment centers situated in California. The firm was established in 2008 and bases its operations in Carlsbad, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:48 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $787.00K+10.34% vs estimate |
| Q3 2019 | Nov 8, 2019 | -$1.83+71.54% vs estimate | $333.00K-71.5% vs estimate |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,430.52+$56.82 (+4.14%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
$2.36+$0.22 (+10.28%)
Xylo Technologies Ltd.’s quoted price sits in the lower half of its reported 52-week range, 67.09% below the high.
$5.80$0.00 (0.0%)
Regional Health Properties, Inc.’s quoted price sits in the lower half of its reported 52-week range, 13.43% below the high.
$0.17+$0.17 (+100.0%)
Holdco Nuvo Group D.G Ltd. Ordinary Shares’s quoted price sits in the lower half of its reported 52-week range, 22.73% below the high.
$0.94-$0.01 (-0.53%)
Fresh Tracks Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 9.44% below the high.
$0.12-$0.08 (-40.69%)
Greenbrook TMS Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.77% below the high.
$0.02-$0.01 (-35.59%)
Invitae Corporation’s quoted price sits in the lower half of its reported 52-week range, 99.19% below the high.
$0.02$0.00 (0.0%)
LumiraDx Limited’s quoted price sits in the lower half of its reported 52-week range, 43.26% below the high.
